“…Conclusion: Outpatient transplantation is a feasible alternative for performing HSCT during the COVID-19 pandemic minimizing the risk of infection and providing a safe environment for patients, donors, and healthcare providers. [Figure: see text] DISCLOSURES: Gomez-Almaguer:Amgen: Membership on an entity's Board of Directors or advisory committees, Speakers Bureau; Novartis: Membership on an entity's Board of Directors or advisory committees, Speakers Bureau; AbbVie: Membership on an entity's Board of Directors or advisory committees, Speakers Bureau; Janssen: Membership on an entity's Board of Directors or advisory committees, Speakers Bureau; Celgene/BMS: Membership on an entity's Board of Directors or advisory committees, Speakers Bureau; AstraZeneca: Membership on an entity's Board of Directors or advisory committees, Speakers Bureau; Pfizer: Membership on an entity's Board of Directors or advisory committees, Speakers Bureau; Roche: Membership on an entity's Board of Directors or advisory committees, Speakers Bureau.…”
Enlace del recurso
Enlace del recurso

“…These observations underscore the importance of prospective randomized controlled studies to address anticoagulation strategies and routine hematologic laboratory monitoring in hospitalized patients with COVID-19. [Figure: see text] DISCLOSURES: De Sancho:Sanofi Genzyme:Membership on an entity's Board of Directors or advisory committees;Apellis Pharmaceuticals:Membership on an entity's Board of Directors or advisory committees;Bio Products Laboratory:Membership on an entity's Board of Directors or advisory committees.…”
Enlace del recurso
Enlace del recurso

“…Increased vWF and decreased ADAMTS13 activity in our cohort could indicate that the underlying mechanism of this coagulopathy may reside in the endothelial cells and share a similar pathogenesis with thrombotic microangiopathy (TMA), as it has been recently suggested in some scientific reports. [Figure: see text] DISCLOSURES: No relevant conflicts of interest to declare.…”
Enlace del recurso
Enlace del recurso

“…Factors associated to this higher mortality should be further investigated to promptly identify high-risk patients since the pandemic is still highly active worldwide. [Figure: see text] DISCLOSURES: Kwon:Gilead: Consultancy, Honoraria; Novartis: Consultancy, Honoraria; Pfizer: Consultancy, Honoraria; Jazz: Consultancy, Honoraria. …”
Enlace del recurso
Enlace del recurso

“…Its high time hospital administrators start taking notice this aspect of healthcare workers and start working on creating a positive work environment. [Figure: see text] DISCLOSURES: No relevant conflicts of interest to declare.…”
Enlace del recurso
Enlace del recurso

“…The etiology behind this association is still unclear and presents an area for future research. [Figure: see text] DISCLOSURES: No relevant conflicts of interest to declare.…”
Enlace del recurso
Enlace del recurso

“…Conclusion:Aside from the known anticoagulant benefit of LMWH, there was no additional anti-inflammatory role with higher doses (1mg/kg/subcutaneously every 12 hours) of LMWH. [Figure: see text] DISCLOSURES: No relevant conflicts of interest to declare.…”
Enlace del recurso
Enlace del recurso

“…However, the systemic immunologic changes in pregnancy and the postpartum period remain largely unknown and prospective studies are needed to further investigate the effects of COVID-19 on pregnant patients. [Figure: see text] DISCLOSURES: No relevant conflicts of interest to declare.…”
Enlace del recurso
Enlace del recurso

“…The clinical relevance of these biomarkers for early detection of hypercoagulability of cellular origin in patients with COVID-19 is being evaluated in prospective study. [Figure: see text] DISCLOSURES: No relevant conflicts of interest to declare.…”
Enlace del recurso
Enlace del recurso

“…Le sex-ratio homme/femme était de 1,1 en P19 et 1,2 en P20. La figure 1 illustre le nombre de cas par mois pour chacun des 6 mois en 2019 et 2020. …”
Enlace del recurso
Enlace del recurso

“…Tumorigenesis correlated with chronic colonization with toxigenic strains of C. difficile and was toxin-dependent, as toxin mutant strains (M7404 tcdA-tcdB-) did not induce tumors. Figure 1. C. difficile strains from CRC patients induce distal colonic tumorigenesis in germ-free (GF) ApcMin/+ mice. …”
Enlace del recurso
Enlace del recurso

“…The size of the lesions in mice infected with OG1RFmadS(A202E) was also significantly larger than those in OG1RF wild type (Fig 1). Figure 1. Cardiac microlesions in a mouse peritonitis model of Enterococcus faecalis infection. …”
Enlace del recurso
Enlace del recurso

“…AA had higher rates of diabetes, hemodialysis, HIV infection for both MSSA and MRSA, but higher rates of injection drug use for MSSA only; Whites had higher rates of neoplasm, corticosteroid use, surgery for MSSA and MRSA, but higher rates of transplant for MRSA only (Figures 1, 2). AA had higher Acute Physiology Scores (MSSA: 9.0 vs 6.0, p< 0.001; MRSA: 8.0 vs 7.0, p=0.005). …”
Enlace del recurso
Enlace del recurso

“…However, statistically, this was represented no agreement by more than chance between preoperative or postoperative pronation on WBCT scans and radiographs (k=.041, P=.774 and k=.059, P=.595, respectively) (Figures 1A-B). Similarly, pronation of the first metatarsal on radiographs did not agree with pronation on WBCT scans using the alpha angle measure either preoperatively or postoperatively (k=.070, P=.474 and k=.063, P=.364, respectively). …”
Enlace del recurso
Enlace del recurso

“…Thus, further studies to analyse the prevalence of AAbs against type I IFNs in patients with MPN, their association with other forms of auto-immunity and severe COVID-19 are warranted. [Figure: see text] DISCLOSURES: Arcaini:  Gilead Sciences: Research Funding; Bayer, Celgene, Gilead Sciences, Roche, Sandoz, Janssen-Cilag, VERASTEM: Consultancy; Celgene, Roche, Janssen-Cilag, Gilead: Other: Travel expenses; Celgene: Speakers Bureau. …”
Enlace del recurso
Enlace del recurso

“…The impact of voxelotor treatment will continue to be assessed in SCD patients at our institution, and more data from clinical encounters will lead to a greater understanding of the efficacy of voxelotor. [Figure: see text] DISCLOSURES: Jain:  GBT: Speakers Bureau; Novartis: Speakers Bureau; Sanofi: Other: advisory board; Argenx: Other: advisory board; DOVA: Other: advisory board.…”
Enlace del recurso
Enlace del recurso

“…Further cases and studies are needed to determine if this is directly linked to SARS-CoV-2 and whether the natural history and response to standard therapy is different than idiopathic cases. [Figure: see text] DISCLOSURES: Young:  Novartis: Research Funding.…”
Enlace del recurso
Enlace del recurso

“…The longer-term follow-up did not reveal any concerns in terms of hem disease outcomes. [Figure: see text] DISCLOSURES: Vorobyev:  Janssen, Roche, Sanofi, Takeda, Biocad, Abbvie: Other: Advisory Boards, Speakers Bureau; Astellas, Novartis, AstraZeneca: Speakers Bureau. …”
Enlace del recurso
Enlace del recurso

“…Br J Cancer 2021; 124(11): 1777-84. [Figure: see text] DISCLOSURES: No relevant conflicts of interest to declare.…”
Enlace del recurso
Enlace del recurso

“…These data can be useful to determine the efficacy of COVID-19 vaccines in patients with OHD. [Figure: see text] DISCLOSURES: Garcia Gutierrez:  BMS: Consultancy, Honoraria, Research Funding; Novartis: Consultancy, Honoraria, Research Funding; Incyte: Consultancy, Honoraria, Research Funding; Pfizer: Consultancy, Honoraria, Research Funding.…”
Enlace del recurso
Enlace del recurso